Cyr61 Expression is associated with prognosis in patients with colorectal cancer

被引:37
|
作者
Jeong, Dongjun [1 ,6 ]
Heo, Suhak [2 ]
Ahn, Tae Sung [3 ]
Lee, Sookyoung [1 ]
Park, Soyoung [1 ]
Kim, Hyungjoo [1 ]
Park, Doosan [1 ]
Bae, Sang Byung [4 ]
Lee, Sung Soo [5 ]
Lee, Moon Soo [3 ]
Kim, Chang-Jin [1 ]
Baek, Moo Jun [3 ]
机构
[1] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan 330722, Chungcheongnam, South Korea
[2] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan 330722, Chungcheongnam, South Korea
[3] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan 330722, Chungcheongnam, South Korea
[4] Soonchunhyang Univ, Coll Med, Dept Oncol, Cheonan 330722, Chungcheongnam, South Korea
[5] Soonchunhyang Univ, Coll Med, Dept Prevent Med, Cheonan 330722, Chungcheongnam, South Korea
[6] Soonchunhyang Univ, Coll Med, Soonchunhyang Med Sci Res Inst, Cheonan 330722, Chungcheongnam, South Korea
来源
BMC CANCER | 2014年 / 14卷
关键词
Colorectal cancer; Cyr61; Immunohistochemistry; Prognosis; IMMEDIATE-EARLY GENE; CELL LUNG-CANCER; GROWTH-FACTOR; BREAST-CANCER; CCN FAMILY; MATRICELLULAR PROTEIN; EXTRACELLULAR-MATRIX; TUMOR-SUPPRESSOR; PROSTATE-CANCER; MIGRATION;
D O I
10.1186/1471-2407-14-164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in cellular processes such as adhesion, migration, proliferation, and survival. Cyr61 can also function as an oncogene or a tumour suppressor, depending on the origin of the cancer. Only a few studies have reported Cyr61 expression in colorectal cancer. In this study, we assessed the Cyr61 expression in 251 colorectal cancers with clinical follow up. Methods: We examined Cyr61 expression in 6 colorectal cancer cell lines (HT29, Colo205, Lovo, HCT116, SW480, SW620) and 20 sets of paired normal and colorectal cancer tissues by western blot. To validate the association of Cyr61 expression with clinicopathological parameters, we assessed Cyr61 expression using tissue microarray analysis of primary colorectal cancer by immunohistochemical analysis. Results: We verified that all of the cancer cell lines expressed Cyr61; 2 cell lines (HT29 and Colo205) demonstrated Cyr61 expression to a slight extent, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyr61 expression than HT29 and Colo205 cell lines. Among the 20 cases of paired normal and tumour tissues, greater Cyr61 expression was observed in 16 (80%) tumour tissues than in normal tissues. Furthermore, 157 out of 251 cases (62.5%) of colorectal cancer examined in this study displayed strong Cyr61 expression. Cyr61 expression was found to be associated with pN (p = 0.018). Moreover, Cyr61 expression was associated with statistically significant cancer-specific mortality (p = 0.029). The duration of survival was significantly lesser in patients with Cyr61 high expression than in patients with Cyr61 low expression (p = 0.001). These results suggest that Cyr61 expression plays several important roles in carcinogenesis and may also be a good prognostic marker for colorectal cancer. Conclusions: Our data confirmed that Cyr61 was expressed in colorectal cancers and the expression was correlated with worse prognosis of colorectal cancers.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Cyr61 Expression is associated with prognosis in patients with colorectal cancer
    Dongjun Jeong
    Suhak Heo
    Tae Sung Ahn
    Sookyoung Lee
    Soyoung Park
    Hyungjoo Kim
    Doosan Park
    Sang Byung Bae
    Sung Soo Lee
    Moon Soo Lee
    Chang-Jin Kim
    Moo Jun Baek
    BMC Cancer, 14
  • [2] Expression of CTGF and Cyr61 in colorectal cancer
    Ladwa, Rahul
    Pringle, Howard
    Kumar, Rohan
    West, Kevin
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (01) : 58 - 64
  • [3] CYR61 expression in prostate cancer patients at City of Hope
    Ortiz-Hernandez, Greisha L.
    Ding, Yuan Chun
    Neuhausen, Susan L.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [4] High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma
    Liu, Yanming
    Zhang, Feiyue
    Zhang, Zhaobo
    Wang, Daoqing
    Cui, Baojuan
    Zeng, Fanshuo
    Huang, Laigang
    Zhang, Qi
    Sun, Qiangsan
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (08) : 895 - 899
  • [5] Pro-angiogenic Factor Cyr61 is Linked to Colorectal Cancer Development and Prognosis
    Baek, M.
    Ahn, T.
    Jung, D.
    Park, S.
    Kim, H.
    Lee, W.
    Park, D.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S137 - S138
  • [6] Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer
    Song, Y. F.
    Xu, Z. B.
    Zhu, X. J.
    Tao, X.
    Liu, J. L.
    Gao, F. L.
    Wu, C. L.
    Song, B.
    Lin, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (04): : 519 - 524
  • [7] Expression of the extracellular matrix associated protein Cyr61 is associated with the development of prostate cancer
    D'Antonio, Katherine
    Toubaji, Antoun
    Albadine, Roula
    Netto, George J.
    Getzenberg, Robert H.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 459 - 459
  • [8] Aberrant activation of CYR61 enhancers in colorectal cancer development
    Lingzhu Xie
    Xuhong Song
    Hao Lin
    Zikai Chen
    Qidong Li
    Tangfei Guo
    Tian Xu
    Ting Su
    Man Xu
    Xiaolan Chang
    Long-Kun Wang
    Bin Liang
    Dongyang Huang
    Journal of Experimental & Clinical Cancer Research, 38
  • [9] CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma
    Shen, Huimin
    Cai, Muyan
    Zhao, Shanshan
    Wang, Huan
    Li, Mengxiong
    Yao, Shuzhong
    Jiang, Nan
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [10] Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer
    Y. F. Song
    Z. B. Xu
    X. J. Zhu
    X. Tao
    J. L. Liu
    F. L. Gao
    C. L. Wu
    B. Song
    Q. Lin
    Clinical and Translational Oncology, 2017, 19 : 519 - 524